KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Cash & Equivalents (2016 - 2025)

Teladoc Health's Cash & Equivalents history spans 13 years, with the latest figure at $781.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 39.84% year-over-year to $781.1 million; the TTM value through Dec 2025 reached $781.1 million, down 39.84%, while the annual FY2025 figure was $781.1 million, 39.84% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $781.1 million at Teladoc Health, up from $726.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.3 billion in Q4 2024 and bottomed at $679.6 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $896.6 million (2021), against an average of $947.0 million.
  • The largest annual shift saw Cash & Equivalents surged 41.77% in 2021 before it plummeted 41.61% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $893.5 million in 2021, then increased by 2.76% to $918.2 million in 2022, then rose by 22.38% to $1.1 billion in 2023, then rose by 15.54% to $1.3 billion in 2024, then tumbled by 39.84% to $781.1 million in 2025.
  • Per Business Quant, the three most recent readings for TDOC's Cash & Equivalents are $781.1 million (Q4 2025), $726.2 million (Q3 2025), and $679.6 million (Q2 2025).